第57回日本てんかん学会学術集会 第57回日本てんかん学会学術集会

Call for abstracts

Abstract submission Due date

General Submissions: March 29, 2024 at noon(Japan Standard Time) Closed
Designated presentations: Nominated speakers will be contacted individually.

Outline

  • Abstracts must be submitted via online system.
  • The text of the abstract can be prepared in Japanese or English
  • Speakers whose sessions include international speakers are asked to submit their abstracts in English.
  • The presenter should be the first author.
  • Foreign presenters currently studying in Japan will be exempt from the registration fee.

Presentation style

General submissions

  1. Oral Japanese presentation
  2. Oral English presentation
  3. Poster presentation.

Please choose from 1, 2, or 3. However, please note that we may not be able to accommodate your request. After peer review by the program committee, you will be notified by email of the acceptance or rejection of your abstract, presentation format, presentation number, etc. by the end of June.

Designated presentations

Oral presentation only

* Those who require any special considerations on the day of the presentation, please provide details by checking the relevant box when submitting abstract (i.e., use of a wheelchair, etc.)

Awards

1. Excellent Poster Award

Awards will be presented to the best poster presentations. Requirements: First author must be under 40 years of age (as of April 1, 2024). If you wish to apply for the Award, please indicate it at the time of your abstract submission.

2. English Presentation Award

Awards will be presented for the best oral presentations in English. Requirements: No age restriction. No need to apply for it.

3. Yes-Japan Award

Awards will be presented to the best poster presentations. Requirements: First author must be under 40 years of age and a medical student, young physician’s early career, or a medical staff.

4. Award

The awarding ceremony will be held on the last day of the exhibition.

Eligibility and conditions

Ethical considerations

Abstracts will be accepted for peer review following confirmation that there are no ethical issues related to the study. Presenters must adhere to the “Declaration of Helsinki” and must bear ethical responsibility for their presentations. Please answer the questions concerning ethical issues at the time of abstract submission. If there are no ethical issue with the contents of your presentation, you do not have to state that in the abstract. Please make certain that you do not disclose private information regarding patients involved in the study.

Abstract overlap

All abstracts must be original and previously unpublished. If your abstract for this congress overlaps with one for another presentation, please send a copy of the other abstract to the Secretariat of the 57th Annual Congress of the Japan Epilepsy Society. 36th International Epilepsy Congress and 57th JES do not compete with each other, and international and domestic abstracts are considered as separate.

JES membership status of first author

The first author must be a regular member or temporary member of the Japan Epilepsy Society. If you are not a member, please apply for membership at the time of abstract submission. More than one regular member must be included as a co-author when a presentation is given by a temporary member.

To apply for membership, please contact the Secretariat of the Japan Epilepsy Society:

URL:http://square.umin.ac.jp/jes/gaiyo/entrance-guide.html
E-mail:jes-oas@umin.ac.jp
TEL and FAX:+81-42-345-2522

Disclosure of Conflicts of Interest (COI)

  • The method of reporting COI has been changed.
    Please answer the "Conflict of Interest (COI)" questions in the system at the time of abstract submission.
  • For the detailed information on the Policy on Conflicts of Interest (COI) in Clinical Research, click here.
  • Please contact the Secretariat of the Japan Epilepsy Society (see below) for any technical questions on COI.
COI Disclosure Form (Template) for Oral and Poster Presentations

Form 2: Disclosure of COI Secretariat of the Japan Epilepsy Society

https://square.umin.ac.jp/jes/index.html
4-6-15 Ogawahigashi-cho, Kodaira City, Tokyo, 187-0031, Japan
E-mail:jes-oas@umin.ac.jp
TEL and FAX:+81-42-345-2522

Submission Guidelines

Number of words

General Submissions (both Oral/Poster presentations)
Japanese English
including spaces
Title Less than 50 characters
(double-byte)
Less than 25 words
(single-byte)
Text* Less than 800 characters
(double-byte)
Less than 220 words
(single-byte)
Total number of words/characters
(author name(s), affiliation(s), abstract title and text)
Less than 1,100 characters
(double-byte)
Less than 300 words
(single-byte)
Designated Presentation
[Japanese] [English]
including spaces
Title Less than 50 characters
(double-byte)
Less than 25 words
(single-byte)
Text* Less than 1,200 characters
(double-byte)
Less than 350 words
(single-byte)
Total number of words/characters
(author name(s), affiliation(s), abstract title and text)
Less than 1,500 characters
(double-byte
Less than 430 words
(single-byte)

* Please structure the abstract using the following headings: Objectives, Subjects and Methods, Results, Conclusion.

Presentation style or session format for designated presentations

* Please select one of the following.

General Submissions
1 Oral Presentation (Japanese/English)
2 Poster Presentation (Japanese/English)
Designated Presentation
1 President’s Lecture
2 Symposium
3 Educational Lecture
4 Supervisor Training
5 Special Lecture in English
6 Others
Category

If you have selected “Oral Presentation” or “Poster Presentation” as your presentation style, please select the categories from the list below.

01 Etiology/Epidemiology
02 Underlying condition/Disease
03 Classification/Syndrome
04 Genetics
05 Ictal semiology
06 EEG/MEG/Neurophysiology
07 Neuroimaging
08 Medication
09 Surgery
10 Other treatment
11 Clinical course/Prognosis
12 Social aspect/QOL
13 Comorbidity
14 Psychiatric symptom
15 Development/Neuropsychology
16 Comprehensive/Integrated care
17 Medical system
18 Medical staff session
19 Adverse effect
20 Pharmacology
21 Physiology
22 Pathology
23 Biochemistry
24 Neurotransmitter
25 Experimental epilepsy
26 Case report
27 Art, History

Abstract submission

New submission
Login to Confirm, Modify, or Withdraw

先頭に戻る